Under the five-year agreement, CRL will be Neuren’s preferred partner for clinical development. CRL presently is supporting Neuren’s phase II clinical research program with NNZ-2566, providing site monitoring, data management and safety reporting services for the trial.
In addition, Dr Jackson Snyder, a CRL assistant managing director, will take on the role of chief medical officer for the US operation, including medical oversight of the NNZ-2566 trial. Dr Snyder is a physician scientist with more than 30 years of experience in clinical trials, pharmaceutical product development, academic research, government operations and clinical medicine.
Allen Cato, president and CEO of CRL, said: “We are pleased to be entering into a strategic relationship with Neuren. Their innovative science and clinical strategy and dedication to making a real difference offer great promise for addressing major unmet medical needs with significant public health consequences. For more than 20 years, Cato Research has worked with and invested in companies with creative, exciting programs to help bring their products to market where the potential impact of the technologies on both medical care and company value is great. Neuren certainly fits this mould and we are looking forward to a long and productive partnership.”
Larry Glass, CEO of Neuren, said: “The expansion of our relationship with Cato represents a major step forward in the Company’s commitment to best-in-class management of drug development. Strategic outsourcing is a cornerstone of our approach to meeting that commitment and Cato will help us to ensure that our clinical development and regulatory activities continue to meet the highest standards as well as to maximize the cost-effectiveness of the operations. I’ve worked with CRL on a number of projects in the past and fully appreciate the benefits of their experience, professionalism and insight.”
CRL is a global contract research organization providing regulatory and clinical research services to the pharmaceutical, biotechnology and medical device industries.